

## Figure 1

### Clone C35

#### A. DNA Coding Sequence

gcc gcg ATG AGC GGG GAG CCG GGG CAG ACG TCC GTA  
GCG CCC CCT CCC GAG GAG GTC GAG CCG GGC AGT  
GGG GTC CGC ATC GTG GTG GAG TAC TGT GAA CCC  
TGC GGC TTC GAG GCG ACC TAC CTG GAG CTG GCC  
AGT GCT GTG AAG GAG CAG TAT CCG GGC ATC GAG  
ATC GAG TCG CGC CTC GGG GGC ACA GGT GCC TTT  
GAG ATA GAG ATA AAT GGA CAG CTG GTG TTC TCC  
AAG CTG GAG AAT GGG GGC TTT CCC TAT GAG AAA  
GAT CTC ATT GAG GCC ATC CGA AGA GCC AGT AAT  
GGA GAA ACC CTA GAA AAG ATC ACC AAC AGC CGT  
CCT CCC TGC GTC ATC CTG TGA

#### B. Protein Sequence

MSGEPGQTSVAPPPEEVEPGSGVRIVVEYCEPCGFEATYLEL  
ASAVKEQYPGIEIESRLGGTGAFEIEINGQLVFSKLENGGFPY  
EKDLIEAIRRASNGETLEKITNSRPPCVIL\*

Figure 2. C35 is Expressed at High Levels in Breast Tumors but Not Normal Tissues






Figure 3




# Figure 4

A.



B.



C.




Figure 5A




Figure 5B

Target	Percent Specific Lysis	
	Effector : Target	
	<u>10:1</u>	<u>2:1</u>
BCA 34	68.4	54.8
BCA 39	36.6	23.4
B/C.N	0.2	0.3
B/C.N + vF5.8	47.5	34.6
B/C.N + vH2.16	67.8	56.2
B/C.N + vaccinia vector	0	0.2

Downloaded from www.jstor.org

B. H2.16

Amino Acid Position	45	46	47	48	49	50	51	52	53	54	55	56
Sequence	A	F	L	G	Y	K	A	G	M	I	H	I
Nucleotide	---	---	---	---	---	---	---	---	---	-T-	---	---

Effector: Target

<u>Target</u>	<u>10:1</u>	<u>2:1</u>
BCA 34	62.4	32.1
BCA 39	49.7	23.6
B/C.N	3.3	0.2
B/C.N + L3 peptide 48-56(I54)	46.0	16.1
B/C.N + L3 peptide 48-56(T54)	2.0	0
B/C.N + L3 peptide 45-54(I54)	0	0

**THE UNIVERSITY OF CHICAGO**



Figure 7B






Figure 8A

Published L3 (1276 bp)



168-171 = GACC

H2.16 (1276 bp)



168-171 = GATC

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Figure 8B




Figure 8C




Figure 9A

Target	Percent Specific Lysis Immunogen			
	vH2.16		v7.5/tk	
	40:1	10:1	40:1	10:1
BCA 34	33.6	12.9	5.7	4.0
BCA 39	22.1	9.0	5.3	3.1
B/C.N + L3 48-56 (I54)	48.2	20.2	3.9	1.5
B/C.N + L3 48-56 (T54)	6.4	1.4	1.8	2.9
B/C.N	7.1	5.7	6.1	2.8
YAC	1.2	2.5	0	1.8





Figure 9C



A.

```

gccccgagcggagccggccgcg ATG AGC GGG GAG CCG GGG CAG ACG TCC
                        M  S  G  E  P  G  Q  T  S
GTA GCG CCC CCT CCC GAG GAG GTC GAG CCG GGC AGT GGG GTC CGC
V  A  P  P  P  E  E  V  E  P  G  S  G  V  R
ATC GTG GTG GAG TAC TGT GAA CCC TGC GGC TTC GAG GCG ACC TAC
I  V  V  E  Y  C  E  P  C  G  F  E  A  T  Y
CTG GAG CTG GCC AGT GCT GTG AAG GAG CAG TAT CCG GGC ATC GAG
L  E  L  A  S  A  V  K  E  Q  Y  P  G  I  E
ATC GAG TCG CGC CTC GGG GGC ACA GGT GCC TTT GAG ATA GAG ATA
I  E  S  R  L  G  G  T  G  A  F  E  I  E  I
AAT GGA CAG CTG GTG TTC TCC AAG CTG GAG AAT GGG GGC TTT CCC
N  G  Q  L  V  F  S  K  L  E  N  G  G  F  P
TAT GAG AAA GAT CTC ATT GAG GCC ATC CGA AGA GCC AGT AAT GGA
Y  E  K  D  L  I  E  A  I  R  R  A  S  N  G
GAA ACC CTA GAA AAG ATC ACC AAC AGC CGT CCT CCC TGC GTC ATC
E  T  L  E  K  I  T  N  S  R  P  P  C  V  I
CTG TGA ctgcacaggactctgggttctctgctctgttctgggggtccaaaccttggtct
L  *
ccctttggtcctgctgggagctccccctgcctcttttcccctacttagctccttagcaaa
gagacctggcctccactttgccctttgggtacaaagaaggaatagaagattccgtggc
cttgggggagcaggagagagacactctccatgaacacttctccagccacctctatcccctt
cccagggttaagtgccacgaaagcccagtcctcttcgcctcggtataacctgtctga
tgccacagattttatttattctcccctaaccagggaatgtcagctatgggcagtaaa
gtggcgctac-polyA

```

B.





Figure 10



## A. Breast epithelial cell lines



## B. Primary breast tissue/tumors






Figure 11

**Primary bladder tumors**



**Figure 12**

## A. BREAST



## B. BLADDER






Figure 13

21NT Breast Tumor




H16N2 Normal Breast



**Figure 14**

### A. Lytic activity of C35-specific T cell line 4



### B. Lytic activity of C35-specific T cell clone 10G3





Figure 15

A.



B.




Figure 16

## Tolerance to Alloantigens Induced in presence of Antigens and Anti-CD40 Ligand Antibody




Figure 17